

Bipolar Disorder Working Group meeting

Date: 13/02/2023

Location: Virtual

Minutes: Confirmed

Committee members present:	
Elizabeth Kay (Chair)	Present for notes 1 – 3
Zoe Pease	Present for notes 1 – 3
Ivan Kennes	Present for notes 1 – 3
Nigel Barnes	Present for notes 1 – 3
Claire Coppens	Present for note 3
Apologies:	
Priya Natarajan	
Aditya Sharma	
Sarah Mee	
Leigh Henderson	

In attendance:		
Angela Bennett	Director of Guidelines, GDT-NGA	Present for notes 1 – 3
Hilary Eadon	Guideline Lead, GDT- NGA	Present for notes 1 - 3
Steve Pilling	Clinical Adviser, GDT- NGA	Present for notes 1 – 3
Odette Megnin-Viggars	Senior Systematic Reviewer, GDT-NGA	Present for notes 1 – 3
Catharine Baden-Daintree	Senior Medical Editor	Present for notes 1 – 3

1. Welcome and objectives for the meeting

The Chair welcomed the members and attendees to the 2nd meeting of the Bipolar Disorder Working Group.

The Chair informed the Working Group that apologies had been received from Priya Natarajan, Aditya Sharma, Sarah Mee and Leigh Henderson.

The Chair outlined the objectives of the meeting, which were to review the recommendations from GC185 about the use of sodium valproate and agree if changes were needed in light of changes made to the regulations by the MHRA.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was use of sodium valproate for the treatment of bipolar disorder

A record of the interests declared by Working Group members is available on the NICE website. No new interests were declared at the meeting.

A senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Presentations and discussion

The Chair introduced Odette Megnin-Viggars, Senior Systematic Reviewer, GDT-NGA who re-presented the effectiveness data for valproate in the treatment of long-term treatment, published since CG185.

The Working Group then discussed the issues presented in relation to long-term management and the recommendations about how to use valproate.

Date of next meeting: 16/2/23

Location of next meeting: Virtual